| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
LiquidSEQ(TM)
Test Code14308
CPT Codes
*ERRO (x0)
Preferred Specimen
10 mL Whole blood [x2].
Collection Instructions:
__** This test is not available for Wyoming patient testing.
__** This test requires two Streck tubes. Blood will be
__collected in office via QUEST-LIQUIDSEQ GEN KIT. Specimens
__may be shipped separately and at different times. Do not
__hold blood specimen due to short stability. Do not reject.
__Blood collection using a straight needle is preferred. Use
__kit only. All tubes must be filled completely. Gently
__invert tube at least 8 times immediately after draw.
Collection Instructions:
__** This test is not available for Wyoming patient testing.
__** This test requires two Streck tubes. Blood will be
__collected in office via QUEST-LIQUIDSEQ GEN KIT. Specimens
__may be shipped separately and at different times. Do not
__hold blood specimen due to short stability. Do not reject.
__Blood collection using a straight needle is preferred. Use
__kit only. All tubes must be filled completely. Gently
__invert tube at least 8 times immediately after draw.
Minimum Volume
10 mL Whole blood [x2]
Transport Container
Whole blood: Streck cell-free DNA blood collection tube [x2]
Transport Temperature
Whole blood: Room temperature preferred; Refrigerated
_unacceptable; Frozen unacceptable
_unacceptable; Frozen unacceptable
Specimen Stability
Whole blood
__Room temperature: 7 Days
__Refrigerated: Unacceptable
__Frozen: Unacceptable
__-70 Degrees: Unacceptable
__Room temperature: 7 Days
__Refrigerated: Unacceptable
__Frozen: Unacceptable
__-70 Degrees: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Do not reject, send to labratory, for testing assessment
Methodology
Next Generation Sequencing
Setup Schedule
A.M. Sets up 3 days a week.
Report Available
Reports in 8 to 11 days.
Clinical Significance
The 523-gene comprehensive genomic profiling panel is
intended to help oncologists deliver precision medicine by
providing personalized genomic analysis of a patient s
blood. This comprehensive panel offers the opportunity for
a broader scope of genomic information compared to single
gene tests or smaller panels and an alternative specimen
type for comprehensive genomic profiling of a patient s
solid tumor. For example, it may be useful for patients
with limited or ill-defined treatment options and for those
considering clinical trials in the event tumor tissue is
not available or insufficient for tissue-based testing.
This panel uses next-generation sequencing to detect
mutations present in circulating tumor DNA (ctDNA)
extracted from a solid tumor patient s blood plasma. The
test is designed to detect single nucleotide variants
(SNVs) and small insertions/deletions, as well as
whole-gene copy number alterations and translocations in a
select group of genes. Microsatellite instability (MSI) and
tumor mutation burden (TMB) are also evaluated.
intended to help oncologists deliver precision medicine by
providing personalized genomic analysis of a patient s
blood. This comprehensive panel offers the opportunity for
a broader scope of genomic information compared to single
gene tests or smaller panels and an alternative specimen
type for comprehensive genomic profiling of a patient s
solid tumor. For example, it may be useful for patients
with limited or ill-defined treatment options and for those
considering clinical trials in the event tumor tissue is
not available or insufficient for tissue-based testing.
This panel uses next-generation sequencing to detect
mutations present in circulating tumor DNA (ctDNA)
extracted from a solid tumor patient s blood plasma. The
test is designed to detect single nucleotide variants
(SNVs) and small insertions/deletions, as well as
whole-gene copy number alterations and translocations in a
select group of genes. Microsatellite instability (MSI) and
tumor mutation burden (TMB) are also evaluated.
